Worth reading
79Important
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
66.9
営業利益の前年比減少率（％）Wording
Definitive
How definitive the wording is.Results for this period
Full year2024年6月1日〜2025年5月31日ConsolidatedJapanese GAAPNet Sales6,077¥ millionYear on year +15.7%Progress 95.0%
Operating profit98¥ millionYear on year -66.9%Progress 36.3%
Ordinary income134¥ millionYear on year -58.1%Progress 57.5%
Net income attributable to owners of the parent-68¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△7.64円
Operating Margin1.6%
Financial position at period-end
Total assets4,080¥ million
of which net assets 1,768 ¥ millionEquity ratio 42.1%vs. prior year-end -5.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-80
Investment-259
Financials+219
Net change-120
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥1,403 million
Segment revenueMedia and Platform Business ¥1,083,286 thousand (YoY -3.7%), Healthcare Institution Management Support Business ¥4,419,419 thousand (YoY +14.3%), Medical B2B Business ¥158,334 thousand (YoY -14.3%), Cloud Integration Business ¥375,076 thousand (YoY +688.9%), Pre-symptomatic disease and prevention platform business ¥41,010 thousand (YoY +58.5%)
Segment profitMedia and Platform Business ¥541,514 thousand (YoY -13.6%), Healthcare Institution Management Support Business ¥190,015 thousand (YoY +1.1%), Medical B2B Business ¥-13,923 thousand, Cloud Integration Business ¥34,280 thousand, Pre-symptomatic disease and prevention platform business ¥-154,410 thousand
Regional sales¥5,135,917 thousand, ¥941,879 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥6,400 million (YoY +5.3%)
Operating profit¥270 million (YoY +173.3%)
Ordinary income¥233 million (YoY +72.4%)
Profit attributable to owners of the parent¥121 million
Annual Dividend Forecast¥3 → ¥3（0.0%）
Payout ratio23.0%
Factors Behind Changes in Business Performance
既存事業の効率化、歯科業界でのプラットフォーム構築や事業拡大により売上高は増加したが、株式会社ミルテルの収益化が実現しなかったことなどにより営業利益は減少した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies (company name: —) / Excluded 1社（株式会社ミルテル）
Material subsequent events株式会社ヨシダとの資本業務提携を締結し、第三者割当による自己株式538,600株の処分を2025年7月18日に完了。処分価額総額は155,116,800円で、資金は事業拡大のためのM&A資金に充当予定。
Impairment loss¥154,709 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of shares in an affiliated company ¥352,546 thousand / Extraordinary loss Provision for allowance for doubtful accounts ¥300,000 thousand, Impairment Losses ¥154,709 thousand, Other ¥7,636 thousand
Depreciation and amortization¥31,050 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and securities analysts)
Issued Shares at Period-End10,773,000
Treasury Shares at Period-End2,041,130
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年6月1日〜2025年5月31日 |
| Net Sales | ¥6,077 million (YoY +15.7%) |
| Operating profit | ¥98 million (YoY -66.9%) |
| Ordinary income | ¥134 million (YoY -58.1%) |
| Profit attributable to owners of the parent | ¥-68 million |
| Net income per share | △7.64円 |
| Operating Margin | 1.6% |
| Equity ratio | End of the current fiscal period 42.1% / End of previous period 47.8% |
| Total assets | ¥4,080 million |
| Net assets | ¥1,768 million |
| Cash flows from operating activities | ¥-80 million |
| Cash flows from investing activities | ¥-259 million |
| Cash flows from financing activities | ¥219 million |
| Cash and cash equivalents at end of period | ¥1,403 million |
| Full-year earnings forecast | Net Sales ¥6,400 million (YoY +5.3%) / Operating profit ¥270 million (YoY +173.3%) / Ordinary income ¥233 million (YoY +72.4%) / Profit attributable to owners of the parent ¥121 million |
| Annual Dividend Forecast | ¥3 → ¥3（0.0%） |
| Payout ratio | 23.0% |
| Segment revenue | Media and Platform Business ¥1,083,286 thousand (YoY -3.7%), Healthcare Institution Management Support Business ¥4,419,419 thousand (YoY +14.3%), Medical B2B Business ¥158,334 thousand (YoY -14.3%), Cloud Integration Business ¥375,076 thousand (YoY +688.9%), Pre-symptomatic disease and prevention platform business ¥41,010 thousand (YoY +58.5%) |
| Segment profit | Media and Platform Business ¥541,514 thousand (YoY -13.6%), Healthcare Institution Management Support Business ¥190,015 thousand (YoY +1.1%), Medical B2B Business ¥-13,923 thousand, Cloud Integration Business ¥34,280 thousand, Pre-symptomatic disease and prevention platform business ¥-154,410 thousand |
| Regional sales | ¥5,135,917 thousand, ¥941,879 thousand |
| Depreciation and amortization | ¥31,050 thousand |
| Impairment loss | ¥154,709 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of shares in an affiliated company ¥352,546 thousand / Extraordinary loss Provision for allowance for doubtful accounts ¥300,000 thousand, Impairment Losses ¥154,709 thousand, Other ¥7,636 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 1社（株式会社ミルテル） |
| Material subsequent events | 株式会社ヨシダとの資本業務提携を締結し、第三者割当による自己株式538,600株の処分を2025年7月18日に完了。処分価額総額は155,116,800円で、資金は事業拡大のためのM&A資金に充当予定。 |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 10,773,000 |
| Treasury Shares at Period-End | 2,041,130 |
| Factors Behind Changes in Business Performance | 既存事業の効率化、歯科業界でのプラットフォーム構築や事業拡大により売上高は増加したが、株式会社ミルテルの収益化が実現しなかったことなどにより営業利益は減少した。 |
Items this document does not state (3)
Revision to Earnings ForecastShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.既存事業の効率化や歯科業界でのプラットフォーム構築などにより事業を拡大したため売上高は増加した。一方、株式会社ミルテルの収益化が実現しなかったことなどにより営業利益は減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.